ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

20.69

+1.01 (5.13%)

Nov 14, 2025, 4:00 PM EST - Market closed

ArriVent BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-150.98	-80.49	-69.33	-36.91	-68.81
Asset Writedown & Restructuring Costs	-	-	-	-	57.21
Stock-Based Compensation	10.25	3.21	0.9	0.42	0.07
Change in Accounts Payable	1.28	-0.75	1.38	2.8	0.39
Change in Other Net Operating Assets	-6.22	7.82	11.22	-9.95	-5.65
Operating Cash Flow	-146.08	-70.21	-55.84	-43.63	-16.78
Sale (Purchase) of Intangibles	-	-	-	-	-53.33
Investment in Securities	-192.49	-192.47	-	-	-
Investing Cash Flow	-192.49	-192.47	-	-	-53.33
Total Debt Issued	-	-	-	-	0.27
Total Debt Repaid	-	-	-	-	-0.27
Issuance of Common Stock	168.45	186.58	0.35	0.02	0
Other Financing Activities	-0.05	-	-2.41	-	-
Financing Cash Flow	168.39	186.58	42.86	169.72	119.82
Net Cash Flow	-170.18	-76.1	-12.98	126.09	49.71
Levered Free Cash Flow	-96.17	-48.64	-32.8	-29.81	-
Unlevered Free Cash Flow	-96.17	-48.64	-32.8	-29.81	-
Change in Working Capital	-4.94	7.07	12.6	-7.15	-5.25

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q